LONG-ACTING INJECTABLE ANTIPSYCHOTICS IN SCHIZOPHRENIA
Boletín de Información Farmacoterapéutica de Navarra · 2023
DOI: 10.54095/bitn20233101en ↗Kurz gefasst
Fachartikel in der Zeitschrift Boletín de Información Farmacoterapéutica de Navarra, 2023. Verfasst von Juan José Beloqui und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Antipsychotics serve as the cornerstone of pharmacological treatment for schizophrenic disorders, including both the management of acute episodes and the prevention of relapse. Longacting injectable antipsychotics (LAIAs) are intended to improve treatment compliance, thereby reducing the risk of relapse and hospitalization. The marketing of LAIAs has increased over the past few years, consequently expanding the range of active substances and extending dosing intervals (bi-weekly, monthly, quarterly and semi-annually). This new situation represents a qualitative change in the available therapeutic approaches for schizophrenia, although a risk/benefit assessment is required, and the prescribing efficiency from an overall patient health perspective needs to be studied.
Zitieren
APA
Beloqui, J. J., Sánchez, M., & Basterra, V. (2023). LONG-ACTING INJECTABLE ANTIPSYCHOTICS IN SCHIZOPHRENIA. Boletín de Información Farmacoterapéutica de Navarra. https://doi.org/10.54095/bitn20233101en
Vancouver
Beloqui JJ, Sánchez M, Basterra V. LONG-ACTING INJECTABLE ANTIPSYCHOTICS IN SCHIZOPHRENIA. Boletín de Información Farmacoterapéutica de Navarra. 2023. doi:10.54095/bitn20233101en
BibTeX
@article{Beloqui2023,
author = {Beloqui, Juan José and Sánchez, María and Basterra, Virginia},
title = {LONG-ACTING INJECTABLE ANTIPSYCHOTICS IN SCHIZOPHRENIA},
journal = {Boletín de Información Farmacoterapéutica de Navarra},
year = {2023},
doi = {10.54095/bitn20233101en}
}
EUVIMED